Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2021
Price :
$35
*
At a glance
- Drugs Vilobelimab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms SHINE
- Sponsors InflaRx
- 11 Feb 2021 According to an InflaRx media release, Data from this study in comparison to healthy volunteers will be presented.
- 11 Feb 2021 According to an InflaRx media release, data from this trial will be presented at the 10th Conference of the European Hidradenitis Suppurativa Foundation, The presentation will take place on February 11, 2021 at 11:30 am EST (5:30 pm CET)
- 11 Feb 2021 Results published in the InflaRx Media Release